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Abstract 
Background: Comprehensive care of people with multiple sclerosis integrates disease modifying therapy, symptom management and 
minimization of risk factors for disease progression. Cigarette smoking is a modifiable risk factor associated with development and 
progression of disease and increased disability. However, little is known about specific factors that affect smoking cessation in patients 
with multiple sclerosis or how to integrate smoking cessation into specialized multiple sclerosis care.  
Methods: Twenty-nine active smokers with multiple sclerosis were surveyed at the James Q. Miller Multiple Sclerosis clinic at the 
University of Virginia Health. Demographics, smoking history, multiple sclerosis history, interest in quitting, barriers to quitting and 
cessation modalities of interest were collected, specifically interest in working with a clinical pharmacist for cessation.  
Results: Seventy-six percent of individuals believed that there was no relationship between smoking and MS diagnosis and 52% were 
unaware of any relationship between smoking and disease progression. Less than half of patients (41%) reported receiving counseling 
from a primary care physician or neurologist about the importance of smoking cessation. Common barriers to quitting included 
enjoyment of smoking (76%) and cravings (55%). Seventy-six percent of patients expressed interest in utilizing pharmacotherapy and 
37% were interested in working closely with a clinical pharmacist.  
Conclusions: It is critical that providers caring for patients with multiple sclerosis assess smoking status and educate smokers about 
the relationship between smoking and disease progression. Efforts should be made to better understand patient-specific barriers to 
quitting and preferred methods of treatment, including pharmacotherapy and behavioral therapy. A multidisciplinary approach to 
smoking cessation that includes a clinical pharmacist may aid in the development of individualized care plans with frequent monitoring 
to improve patient success.  
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Introduction 
While multiple sclerosis (MS) remains a complex immune-
mediated disease, significant advances in research have 
informed clinical practice and improved our ability to effectively 
care for this patient population. Recognized risk factors for the 
development of MS include non-modifiable factors such as age, 
gender and geographic latitude and modifiable risk factors such 
as vitamin D level and tobacco use.1,2 Caring for a patient with 
MS requires a comprehensive approach which integrates both 
disease modifying therapy (DMT) and symptom management. 
The increased identification and recognition of modifiable risk 
factors has expanded patient care to include efforts to minimize 
risk factors, where possible. 
 
The association between cigarette smoking and multiple 
sclerosis development and progression has become more 
evident over the last several decades based upon 
epidemiological data and focused research. A prospective 
evaluation of women enrolled in the Nurses’ Health Studies I 
and II found that the relative incidence of developing multiple 
sclerosis was 1.6 among active smokers compared to 1.2 among 
past smokers. This study also found a significant increase in  
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relative incidence rate when accounting for cumulative 
exposure to cigarette smoking over time.3 A meta-analysis 
conducted by Handel and colleagues in 2011 demonstrated 
that smokers were nearly 1.5 times more likely to develop MS 
than non-smokers.4 In addition to increasing the risk of 
developing multiple sclerosis, tobacco use also influences 
disease progression. Those who smoke will progress to a 
secondary progressive state of multiple sclerosis at a more 
rapid rate than non-smokers. Additionally, smokers may 
experience more severe disability.5 Due to its potential to 
influence disease progression and improve the overall health of 
the MS population, smoking cessation counseling should be 
included in all comprehensive care plans.  
 
The James Q. Miller Multiple Sclerosis clinic at the University of 
Virginia Health (UVaH) cares for nearly 1,500 patients each 
year. The multiple sclerosis clinic consists of a multidisciplinary 
team including neurologists, a nurse practitioner, nursing staff, 
physical and occupational therapists, a pharmacy technician 
and a clinical pharmacist. The clinical pharmacist plays an 
integral role in providing access to disease-modifying therapy, 
ongoing monitoring, patient education and symptomatic 
management. As comprehensive care providers, pharmacists 
are in a unique position to develop strong patient relationships 
and support patients through their smoking cessation journey. 
Based upon regional data and provider survey, nearly 20% of 
patients in the James Q. Miller MS Clinic are tobacco users. The 
purpose of this study was to characterize this patient 
population, assess knowledge about the implications of 
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tobacco use on MS diagnosis and progression, assess patient 
interest in tobacco cessation and identify strategies for 
developing personalized tobacco cessation plans.   
 
Methods 
This study met exempt criteria through the UVA Health 
Institutional Review Board, as smoking cessation is standard of 
care. Eligible patients were identified by electronic medical 
record reporting based upon self-reported tobacco use. 
Beginning in June 2019, an optional 15-item survey was 
distributed to active tobacco users in the James Q. Miller MS 
Clinic during clinic visits (Appendix 1). Patients also received an 
educational brochure developed by the pharmacist. If the 
patient expressed interest in working with a clinical pharmacist 
for smoking cessation, the patient was then contacted by the 
pharmacist to begin development of a personalized cessation 
plan. This individualized plan included prescribing of 
pharmacotherapy through a collaborative practice agreement 
with the neurologists and nurse practitioner in the MS clinic. 
The pharmacist then followed and monitored at a frequency 
determined by the patient.   
Results 
A total of 29 surveys were completed during face-to-face clinic 
visits from June to October 2019. Demographic data is outlined 
in Table 1. Approximately 93% of patients started smoking prior 
to their diagnosis of multiple sclerosis. Interestingly, 76% of 
patients believed that there was no relationship between 
smoking and MS diagnosis and 52% were unaware of any 
relationship between smoking and disease progression. Less 
than half of patients (41%) reported receiving counseling from 
a primary care physician or neurologist about the importance 
of smoking cessation.  
In the preceding year, 58% of patients quit smoking for a 
duration of at least 24 hours on at least one occasion and 10% 
of patients reported quitting five or more times.  Eighty-six 
percent were considering quitting and 37% reported interest in 
working with a clinical pharmacist to do so. Moderate or 
extreme barriers to successful cessation included enjoyment of 
smoking (76%) and cravings (55%). Twenty seven percent of 
patients were concerned about the cost of medication and 
other resources, 14% of patients reported fear of failing and 
10% felt there was lack of support. 
Over 60% of patients reported that group classes would not be 
helpful for cessation and instead anticipated success with the 
following methods: pharmacotherapy (76%), self-help 
educational materials (54%), individual counseling via 
telephone (48%) and communication via an online health portal 
(44%). More patients were interested in slowly reducing the 
number of cigarettes per day (85%) compared to quitting cold 
turkey (45%).  
 
Successful smoking cessation requires a multifaceted approach 
that includes addressing behavioral methods to reduce cravings 
and break habits, approaches to minimize the influence of 
environmental and social factors and thorough discussion 
about pharmacotherapeutic options. As healthcare providers, 
it is important to recognize and understand that smoking 
cessation is a highly individualized process requiring careful 
consideration of patient-specific factors.  
Conclusions 
Smoking cessation should be incorporated as a standard of care 
in all multiple sclerosis centers. Clinical pharmacists are in a 
unique position to assist in the development, implementation 
and monitoring of individualized smoking cessation plans. 
Including pharmacists on the multidisciplinary team allows 
them to serve as clinical extenders and dedicate additional time 
and resources to support patients in an individualized way. Few 
patients anticipate success by quitting “cold turkey”, therefore 
smoking cessation in many cases may be a slower process that 
should be closely monitored with frequent communication. 
This frequent communication is the foundation of pharmacist-
patient relationships that are essential for overcoming the 
inherent challenges of smoking cessation. Collaborative 
practice agreements, which can vary by state, afford clinical 
pharmacists the opportunity to closely engage in smoking 
cessation efforts by prescribing and adjusting pharmacotherapy 
for cessation. Pharmacists should be involved in discussions 
about the appropriateness of prescription and non-prescription 
pharmacotherapy and can help navigate cost and access to 
these therapies. This particularly engaged patient population 
prefers communication via telephone or health portal which 
lends the opportunity for clinical pharmacists to participate in 
telehealth. Additionally, MS teams should embrace the role of 
the clinical pharmacist as the patient educator. The long-term 
health consequences of tobacco use including cardiovascular 
disease and lung disease may be clear to most, but there is an 
apparent knowledge gap about the neurologic effects of 
smoking in patients with MS. Written education, such as self-
help educational materials, should be made available to all 
patients and reinforced through verbal communication during 
clinic visits. Unlike many other factors that influence multiple 
sclerosis development and progression, tobacco use is one that 
is modifiable. It is our responsibility as healthcare providers to 
educate and empower patients using a personalized approach 
to make these positive changes. Future studies should evaluate 
the impact of pharmacist involvement on tobacco cessation 
rates in this patient population.  
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Table 1. Patient Demographics 
 
Characteristic n (%) 
Gender 
     Female 
 
18 (62) 
Age (years) 
     26-30 
     31-40 
     41-50 
     > 50 
 
4 (14) 
12 (41) 
8 (28) 
4 (14) 
Age at MS diagnosis 
     < 20 
     21-25 
     26-30 
     31-35 
     36-40 
     41-45 
     46-50 
     51+ 
 
1 (3) 
4 (14) 
7 (24) 
5 (17) 
1 (3) 
3 (10) 
0 (0) 
2 (7) 
 
Number of years smoked per lifetime 
     1-5 
     5-10 
     10-15 
     > 15 
 
2 (7) 
2 (7) 
6 (21) 
19 (65) 
Number of cigarettes smoked per day 
     < 10 
     10-20  
     21-30 
     31-40 
 
9 (31) 
12 (41) 
5 (17) 
2 (7) 
 
 
 
 
  
Case Study PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                        2020, Vol. 11, No. 2, Article 6                         INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v11i2.3210 
5 
 
 
Appendix 1. Smoking Cessation Patient Survey 
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